前列腺癌预测模型研究的样本量极少被论证且常不充足
该系统综述纳入211个前列腺癌临床预测模型,比较其报告样本量与传统EPP≥10规则及正式样本量标准的符合程度。仅3项研究对样本量进行论证,69%的模型样本量超过EPP≥10规则,但仅48%达到正式样本量标准。多数模型按正式标准所需样本量高于满足10 EPP的样本量。
要点
- 前列腺癌预测模型研究中仅3项对样本量进行了论证,且多基于EPP经验规则。
- 69%的模型样本量超过传统EPP≥10规则,但仅48%达到正式样本量标准。
- 按正式标准,多数模型所需样本量高于满足10 EPP规则所需样本量。
核心结论
- 纳入的前列腺癌预测模型中极少对样本量进行论证,且多数论证基于EPP经验规则。
- 在真实世界数据集中,遵循经典EPP经验规则不足以满足近期正式样本量标准。
研究设计与样本
- 系统综述,纳入211个前列腺癌相关临床预测模型,均提供足够信息以计算最小样本量。
- 将每个模型报告的样本量与传统10 EPP经验规则及正式样本量标准进行比较。
主要发现
- 211个模型中仅3项研究对所用样本量进行了论证,多数使用EPP经验规则。
- 69%的模型推导样本量超过传统EPP≥10经验规则。
- 仅48%的模型样本量超过近期正式样本量标准。
- 对多数模型而言,基于正式标准所需的样本量高于满足10 EPP所需的样本量。
关键数值与推荐
- 传统经验规则:每预测参数事件数(EPP)≥10。
- 正式样本量标准:原文未具体列出。
临床怎么用
- 开发前列腺癌临床预测模型时,应依据正式样本量标准进行样本量论证,而非仅依赖EPP≥10经验规则。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Developing clinical prediction models (CPMs) on data of sufficient sample size is critical to help minimize overfitting. Using prostate cancer as a clinical exemplar, we aimed to investigate to what extent existing CPMs adhere to recent formal sample size criteria, or historic rules of thumb of events per predictor parameter (EPP)≥10. STUDY DESIGN AND SETTING: A systematic review to identify CPMs related to prostate cancer, which provided enough information to calculate minimum sample size. We compared the reported sample size of each CPM against the traditional 10 EPP rule of thumb and formal sample size criteria. RESULTS: About 211 CPMs were included. Three of the studies justified the sample size used, mostly using EPP rules of thumb. Overall, 69% of the CPMs were derived on sample sizes that surpassed the traditional EPP≥10 rule of thumb, but only 48% surpassed recent formal sample size criteria. For most CPMs, the required sample size based on formal criteria was higher than the sample sizes to surpass 10 EPP. CONCLUSION: Few of the CPMs included in this study justified their sample size, with most justifications being based on EPP. This study shows that, in real-world data sets, adhering to the classic EPP rules of thumb is insufficient to adhere to recent formal sample size criteria.
引用
- Collins SD, Peek N, Riley RD, et al. Sample sizes of prediction model studies in prostate cancer were rarely justified and often insufficient. J Clin Epidemiol. 2020. PMID: 33383128. doi:10.1016/j.jclinepi.2020.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。